{"rows":[{"id":5003,"title":"Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer","authors":"Rayyan Zafar, Dustin Sulak, Jaime Brambila, David Nutt, Anne Katrin Schlag","journal":"Drug Science Policy and Law","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1177/20503245221114323","pubmed_id":null,"openalex_id":"https://openalex.org/W4296882666","source_url":"https://doi.org/10.1177/20503245221114323","substance_tags":"psilocybin","topic_tags":"End-of-Life Distress,Chronic Pain,Pharmacology,Cancer Patients","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:58","last_checked":"2026-08-09 08:25:43","bibtex":null,"source_record_id":"DOI:10.1177/20503245221114323","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245221114323","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245221114323","source_url":"https://doi.org/10.1177/20503245221114323","doi":"10.1177/20503245221114323","pmid":"","publication_date":"2022-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4998,"title":"An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma","authors":"F. N. Smith, Joanna C. Neill, Verity Wainwright","journal":"Drug Science Policy and Law","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1177/20503245221124117","pubmed_id":null,"openalex_id":"https://openalex.org/W4295169116","source_url":"https://doi.org/10.1177/20503245221124117","substance_tags":"psilocybin","topic_tags":"Clinical Trial,Veterans,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:58","last_checked":"2026-08-09 08:25:43","bibtex":null,"source_record_id":"DOI:10.1177/20503245221124117","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245221124117","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245221124117","source_url":"https://doi.org/10.1177/20503245221124117","doi":"10.1177/20503245221124117","pmid":"","publication_date":"2022-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4995,"title":"Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness","authors":"Christina Sagioglou, Matthias Forstmann","journal":"Drug Science Policy and Law","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1177/20503245221129803","pubmed_id":null,"openalex_id":"https://openalex.org/W4313144374","source_url":"https://doi.org/10.1177/20503245221129803","substance_tags":"psilocybin","topic_tags":"Addiction,Emotional Processing,Observational Study","study_type":"Observational Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:58","last_checked":"2026-08-09 08:25:43","bibtex":null,"source_record_id":"DOI:10.1177/20503245221129803","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245221129803","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245221129803","source_url":"https://doi.org/10.1177/20503245221129803","doi":"10.1177/20503245221129803","pmid":"","publication_date":"2022-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4879,"title":"Italian psychedelic therapies of the past century: An historical overview","authors":"Adriana D’Arienzo, Giorgio Samorini","journal":"Drug Science Policy and Law","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/20503245231179687","pubmed_id":null,"openalex_id":"https://openalex.org/W4379659828","source_url":"https://doi.org/10.1177/20503245231179687","substance_tags":"psilocybin","topic_tags":"Depression,Receptor Pharmacology","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:46","last_checked":"2026-08-09 08:25:38","bibtex":null,"source_record_id":"DOI:10.1177/20503245231179687","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245231179687","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245231179687","source_url":"https://doi.org/10.1177/20503245231179687","doi":"10.1177/20503245231179687","pmid":"","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4865,"title":"A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness","authors":"Jaden Brandt","journal":"Drug Science Policy and Law","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/20503245231170340","pubmed_id":null,"openalex_id":"https://openalex.org/W4367153945","source_url":"https://doi.org/10.1177/20503245231170340","substance_tags":"psilocybin","topic_tags":"Toxicity","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:46","last_checked":"2026-08-09 08:25:38","bibtex":null,"source_record_id":"DOI:10.1177/20503245231170340","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245231170340","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245231170340","source_url":"https://doi.org/10.1177/20503245231170340","doi":"10.1177/20503245231170340","pmid":"","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4864,"title":"Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use","authors":"Brian S. Barnett, Noah Wiles Sweat, Peter S. Hendricks","journal":"Drug Science Policy and Law","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1177/20503245231172536","pubmed_id":null,"openalex_id":"https://openalex.org/W4367723807","source_url":"https://doi.org/10.1177/20503245231172536","substance_tags":"psilocybin","topic_tags":"Addiction,Mechanism of Action,Case Report,Observational Study","study_type":"Case Report","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:46","last_checked":"2026-08-09 08:25:38","bibtex":null,"source_record_id":"DOI:10.1177/20503245231172536","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245231172536","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245231172536","source_url":"https://doi.org/10.1177/20503245231172536","doi":"10.1177/20503245231172536","pmid":"","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4863,"title":"From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia","authors":"Octavian Dixon Ritchie, Cameron N Donley, Gabrielle Dixon Ritchie","journal":"Drug Science Policy and Law","publication_date":"2022-12-31","publication_year":2022,"doi":"10.1177/20503245231198472","pubmed_id":null,"openalex_id":"https://openalex.org/W4386522609","source_url":"https://doi.org/10.1177/20503245231198472","substance_tags":"psilocybin","topic_tags":"Toxicity","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:46","last_checked":"2026-07-04 07:00:37","bibtex":null,"source_record_id":"DOI:10.1177/20503245231198472","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245231198472","source_url":"https://doi.org/10.1177/20503245231198472","doi":"10.1177/20503245231198472","pmid":"","publication_date":"2022-12-31","importer_version":"2.1.3","text_redistributed":false}},{"id":4409,"title":"Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective","authors":"Octavian Brinzei","journal":"Drug Science Policy and Law","publication_date":"2025-04-01","publication_year":2025,"doi":"10.1177/20503245251337360","pubmed_id":null,"openalex_id":"https://openalex.org/W4409956273","source_url":"https://doi.org/10.1177/20503245251337360","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:40","last_checked":"2026-08-09 08:25:22","bibtex":null,"source_record_id":"DOI:10.1177/20503245251337360","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245251337360","source_url":"https://doi.org/10.1177/20503245251337360","doi":"10.1177/20503245251337360","pmid":"","publication_date":"2025-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4408,"title":"Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness","authors":"Sean M. Viña","journal":"Drug Science Policy and Law","publication_date":"2025-04-01","publication_year":2025,"doi":"10.1177/20503245251337357","pubmed_id":null,"openalex_id":"https://openalex.org/W4409677856","source_url":"https://doi.org/10.1177/20503245251337357","substance_tags":"psilocybin","topic_tags":"Depression,Observational Study","study_type":"Observational Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:40","last_checked":"2026-08-09 08:25:22","bibtex":null,"source_record_id":"DOI:10.1177/20503245251337357","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245251337357","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245251337357","source_url":"https://doi.org/10.1177/20503245251337357","doi":"10.1177/20503245251337357","pmid":"","publication_date":"2025-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4303,"title":"A lexicon for psychedelic research and treatment","authors":"David Nutt, David Erritzøe, Anne Katrin Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, Matthew X. Lowe, Oliver Davis, Plinio Ferreira, Rayyan Zafar, Robin Carhart-Harris, Tadeusz Hawrot, Joanna C. Neill","journal":"Drug Science Policy and Law","publication_date":"2025-08-31","publication_year":2025,"doi":"10.1177/20503245251380511","pubmed_id":null,"openalex_id":"https://openalex.org/W4414407628","source_url":"https://doi.org/10.1177/20503245251380511","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Microdosing,Clinical Trial,Treatment-Resistant Depression,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:39","last_checked":"2026-07-04 07:00:33","bibtex":null,"source_record_id":"DOI:10.1177/20503245251380511","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245251380511","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245251380511","source_url":"https://doi.org/10.1177/20503245251380511","doi":"10.1177/20503245251380511","pmid":"","publication_date":"2025-08-31","importer_version":"2.1.3","text_redistributed":false}},{"id":4150,"title":"The impact of drug control on wider research: Psychedelic mushroom exploration","authors":"Sam Lasham, Rhys Ponton","journal":"Drug Science Policy and Law","publication_date":"2026-01-01","publication_year":2026,"doi":"10.1177/20503245251412697","pubmed_id":null,"openalex_id":"https://openalex.org/W7119482083","source_url":"https://doi.org/10.1177/20503245251412697","substance_tags":"psilocybin","topic_tags":"Pharmacology,Toxicity","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:37","last_checked":"2026-08-09 08:25:13","bibtex":null,"source_record_id":"DOI:10.1177/20503245251412697","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/20503245251412697","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/20503245251412697","source_url":"https://doi.org/10.1177/20503245251412697","doi":"10.1177/20503245251412697","pmid":"","publication_date":"2026-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":3947,"title":"2018: A watershed year for psychedelic science","authors":"Jacob S. Aday, Christopher C. Davoli, Emily K. Bloesch","journal":"Drug Science Policy and Law","publication_date":"2019-01-01","publication_year":2019,"doi":"10.1177/2050324519872284","pubmed_id":null,"openalex_id":"https://openalex.org/W2971831602","source_url":"https://doi.org/10.1177/2050324519872284","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Treatment-Resistant Depression","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-02 20:42:13","last_checked":"2026-08-09 08:25:50","bibtex":null,"source_record_id":"DOI:10.1177/2050324519872284","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/2050324519872284","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/2050324519872284","source_url":"https://doi.org/10.1177/2050324519872284","doi":"10.1177/2050324519872284","pmid":"","publication_date":"2019-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":3881,"title":"Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017","authors":"JEC Anthony, Adam Winstock, JA Ferris, DJ Nutt","journal":"Drug Science Policy and Law","publication_date":"2020-01-01","publication_year":2020,"doi":"10.1177/2050324520942345","pubmed_id":null,"openalex_id":"https://openalex.org/W3096479563","source_url":"https://doi.org/10.1177/2050324520942345","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology,Observational Study","study_type":"Observational Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-02 20:42:13","last_checked":"2026-08-09 08:25:49","bibtex":null,"source_record_id":"DOI:10.1177/2050324520942345","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/2050324520942345","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/2050324520942345","source_url":"https://doi.org/10.1177/2050324520942345","doi":"10.1177/2050324520942345","pmid":"","publication_date":"2020-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":3880,"title":"Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts","authors":"Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers","journal":"Drug Science Policy and Law","publication_date":"2020-01-01","publication_year":2020,"doi":"10.1177/2050324519900068","pubmed_id":null,"openalex_id":"https://openalex.org/W3004031348","source_url":"https://doi.org/10.1177/2050324519900068","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology,Wellbeing,Personality Change,Emotional Processing,Adverse Events","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-02 20:42:13","last_checked":"2026-08-09 08:25:49","bibtex":null,"source_record_id":"DOI:10.1177/2050324519900068","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1177/2050324519900068","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1177/2050324519900068","source_url":"https://doi.org/10.1177/2050324519900068","doi":"10.1177/2050324519900068","pmid":"","publication_date":"2020-01-01","importer_version":"2.1.3","text_redistributed":false}}],"total":14,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Drug Science Policy and Law","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}